Dublin-based SynOx Therapeutics Secures $75Million in Series B Round Funding

Forbion, HealthCap, and new investor Bioqube Ventures co-led the investment. Both Bioqube Ventures' Jon Edwards, PhD, and Forbion's Dr. Carlo Incerti, M.D., have joined the board of directors as a result of the Series B fundraising.

The money will be used by the business to provide registrational Phase 3 clinical and CMC data for emactuzumab, a monoclonal antibody (mAb) that inhibits CSF-1(R) and may be the best in class for treating Tenosynovial Giant Cell Tumours (TGCT).

SynOx Therapeutics, a clinical biopharmaceutical firm led by Chief Executive Officer Ray Barlow, is creating emactuzumab, a best-in-class monoclonal antibody against CSF-1R, to treat Tenosynovial Giant Cell Tumour (TGCT) and other illnesses related to CSF-1 and macrophage driven.

Read also - Poland-based bValue Secures €90Million in Funding

A brand-new, next-generation CSF-1R monoclonal antibody called emactuzumab may have the greatest profile in its class. Emactuzumab showed notable clinical performance in prior TGCT clinical trials, with an objective response rate (ORR) of 71%, a quick and strong reduction in tumour size, a prolonged duration of action, and notable gains in functional capacity.

Significantly, these investigations also showed that emactuzumab had a controllable safety profile and high tolerability. To evaluate the effectiveness and safety of emactuzumab in patients with localised and diffuse TGCT, SynOx is starting the Phase 3 study TANGENT.

About SynOx Therapeutics Ltd.

Founded in November 2020, SynOx Therapeutics Ltd.'s only goal is to develop emactuzumab for use in treating diffuse tenosynovial giant cell tumours (TGCT) and other conditions. With a solid track record of developing biopharma enterprises, SynOx has the support of a syndicate of investors.